Indoco Remedies is currently trading at Rs. 204.55, up by 5.20 points or 2.61% from its previous closing of Rs. 199.35 on the BSE.

The scrip opened at Rs. 200.85 and has touched a high and low of Rs. 214.05 and Rs. 198.70 respectively. So far 6235 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 348.10 on 17-Jul-2025 and a 52 week low of Rs. 190.00 on 28-Feb-2025.

Last one week high and low of the scrip stood at Rs. 214.05 and Rs. 195.40 respectively. The current market cap of the company is Rs. 1888.07 crore.

The promoters holding in the company stood at 58.90%, while Institutions and Non-Institutions held 19.25% and 21.86% respectively.

Indoco Remedies has secured final Abbreviated New Drug Application (ANDA) approval from United States Food and Drug Administration (USFDA) to market its ANDA for Brivaracetam Oral Solution, 10 mg/mL. Brivaracetam Oral Solution, 10 mg/mL, have been determined to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Briviact 10 mg/mL of UCB, Inc. Brivaracetam Oral Solution will be manufactured by the company at its manufacturing facility located at Verna, Goa. 

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.